ASX:BNO Bionomics (BNO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Bionomics Stock (ASX:BNO) 30 days 90 days 365 days Advanced Chart Get Bionomics alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume386,458 shsAverage VolumeN/AMarket Capitalization$13.22 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewBionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.Read More… Receive BNO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bionomics and its competitors with MarketBeat's FREE daily newsletter. Email Address BNO Stock News HeadlinesBNO Makes Bullish Cross Above Critical Moving AverageOctober 5, 2024 | nasdaq.comBionomics Ltd: Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA on the Development of BNC210 in Post-Traumatic Stress DisorderAugust 2, 2024 | finanznachrichten.deGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. Now… as new tariffs take effect, gold is breaking records again. You've hopefully already seen this in action… but gold is surpassing $3,000 per ounce for the first time EVER.May 6, 2025 | Premier Gold Co (Ad)Bionomics ADR (BNOX) Earnings Dates & ReportsDecember 18, 2023 | investing.comBionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic GrowthJuly 3, 2023 | finance.yahoo.comBionomics Ltd: Bionomics Reports Promising Full Results Analysis from PREVAIL Phase 2 Study of BNC210 Social Anxiety Disorder (SAD)March 9, 2023 | finanznachrichten.deBionomics First Half 2023 Earnings: AU$0.012 loss per share (vs AU$0.013 loss in 1H 2022)February 24, 2023 | finance.yahoo.comBionomics Ltd: Bionomics' Half-Year ReportFebruary 23, 2023 | finanznachrichten.deSee More Headlines BNO Stock Analysis - Frequently Asked Questions How were Bionomics' earnings last quarter? Bionomics Limited (ASX:BNO) issued its quarterly earnings data on Friday, February, 15th. The company reported ($0.02) EPS for the quarter. Bionomics had a negative trailing twelve-month return on equity of 116.12% and a negative net margin of 14,558.34%. What other stocks do shareholders of Bionomics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bionomics investors own include McDermott International (MDR), Pacific Drilling (PACDQ), OreCorp (ORR), ORBCOMM (ORBC), Lithium Power International (LPI), Lithium Australia (LIT) and Coca-Cola (KO). Company Calendar Last Earnings2/15/2019Today5/06/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:BNO CIKN/A Webwww.bionomics.com.au Phone+61-8-83546100FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,910,000.00 Net Margins-14,558.34% Pretax MarginN/A Return on Equity-116.12% Return on Assets-20.98% Debt Debt-to-Equity Ratio0.20 Current Ratio3.30 Quick Ratio12.02 Sales & Book Value Annual Sales$6.02 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow2.69 Book ValueA$1.09 per share Price / BookN/AMiscellaneous Outstanding Shares1,470,000,000Free FloatN/AMarket Cap$13.22 million OptionableNot Optionable Beta2.13 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (ASX:BNO) was last updated on 5/6/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredREVEALED: Elon’s Secret Master Plan “AGENDA X”REVEALED: Elon's Secret Master Plan "AGENDA X" For almost 30 years, Elon worked on his master plan in secre...Brownstone Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredTrump's $500B plan is fueling these monthly dividendsSomething extraordinary happened just 24 hours after Trump returned to office... He signed a document that ...Investors Alley | SponsoredConfidential Economic AdvisoryI've hesitated for months to record this video. The very act of sharing these details makes me deeply uncom...InvestorPlace | SponsoredThe New ElonThe New Face of DOGE? There is now a new, powerful and controversial figure at the heart of the DOGE agenda...Altimetry | SponsoredOur #1 Defense Stock for MayWe've already lost 18 straight simulated war games against China. The good news is, the U.S. military has a...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bionomics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Bionomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.